Health-Care Stocks: Growing Like Gangbusters

These health-care stocks offer great growth prospects.

Mar 15, 2014 at 9:30AM

Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some health-care stocks to your portfolio but don't have the time or expertise to hand-pick a few, the Health Care Select Sector SPDR ETF (NYSEMKT:XLV) could save you a lot of trouble. Instead of trying to figure out which stocks will perform best, you can use this ETF to invest in lots of them simultaneously.

The basics
ETFs often sport lower expense ratios than their mutual fund cousins. This ETF, focused on health-care stocks, sports a very low expense ratio -- an annual fee -- of 0.16%.

This health-care stocks ETF has outperformed the world market over the past five, 10, and 15 years. As with most investments, of course, we can't expect outstanding performances in every quarter or year. Investors with conviction need to wait for their holdings to deliver.

Why health-care stocks?
For starters, our planet's growing and aging population will keep demand rising for health-care products and services. On top of that, Obamacare is ushering more Americans into health coverage, delivering more consumers to companies treating them – and thus boosting the prospects for many health-care stocks.

More than a handful of health-care stocks had strong performances over the past year. Regeneron Pharmaceuticals, (NASDAQ:REGN), for example, surged 91%, partly on the success of its wet age-related macular degeneration drug, Eylea (which may soon gain FDA approval to treat diabetic macular edema, too). Eylea generated close to $2 billion in sales last year. Regeneron has lots of irons in the fire, including treatments for high cholesterol and rheumatoid arthritis, which it's developing in partnership with Sanofi. (The FDA has recently expressed concerns about the cholesterol-lowering drug.)

Gilead Sciences (NASDAQ:GILD) popped 70%, with investors excited about its recently approved oral hepatitis-C treatment, Sovaldi, with its reported cure rates near 90% in clinical trials. Insurers and medical bigwigs are less excited, though, objecting to its very steep price tag of around $84,000 for a 12-week course. The company's fourth quarter was strong, with revenue up 21% on strong new-product sales. Sovaldi has the potential to become a blockbuster , with sales exceeding $1 billion. Meanwhile, Sales of Gilead's HIV drug Stribild are growing rapidly, and it might achieve blockbuster status this year, too.

Celgene Corporation (NASDAQ:CELG), another biotech concern, is on a roll, thanks in part to its anemia drug, Revlimid, which now contributes 65% of revenue. It's not ideal to depend on one product so much, but as my colleague Stephen Simpson has noted, Celgene has "a deep early stage pipeline of oncology drugs" and "meaningful label expansion opportunities for approved drugs." It appears to be undervalued, too, with its forward P/E ratio near 17 and EPS growth expected between about 20% and 30% over the next few years.

Other health-care stocks didn't do quite as well over the past year, but could see their fortunes change in the coming years. Allergan (NYSE:AGN), for example, only grew 17%, but it has been beating the S&P 500 lately. It's perhaps best known for its Botox formula, but many don't realize that Botox is also approved to treat conditions other than normal aging, such as migraine headaches and overactive bladders. Some worry about patent expiration for its dry-eye treatment Restasis, but bulls like its strong balance sheet and free cash flow, which could help it acquire smaller companies and their drugs. It's also expected to grow its earnings by double digits in the coming years.

The big picture
If you're interested in adding some health-care stocks to your portfolio, consider doing so via an ETF. A well-chosen ETF can grant you instant diversification across any industry or group of companies -- and make investing in and profiting from it that much easier.

A new approach to cancer treatment
For even more compelling investment ideas, check out The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," detailing a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Selena Maranjian, whom you can follow on Twitter, owns shares of Celgene, Gilead Sciences, and Regeneron Pharmaceuticals. The Motley Fool recommends Celgene and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers